



Protective Antibodies Against Influenza Proteins

Herbey O. Padilla-Quirarte^{1,2*}, Delia V. Lopez-Guerrero³, Lourdes Gutierrez-Xicotencatl⁴ and Fernando Esquivel-Guadarrama^{1*}

¹ LIV, Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Mexico, ² Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico, ³ Facultad de Nutrición, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico, ⁴ Centro de Investigaciones Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico

OPEN ACCESS

Edited by:

Luis F. García,
University of Antioquia, Colombia

Reviewed by:

Florian Krammer,
Icahn School of Medicine at Mount
Sinai, United States
Elisa Vicenzi,
San Raffaele Hospital (IRCCS), Italy

*Correspondence:

Herbey O. Padilla-Quirarte
herbey_oswaldo@hotmail.com
Fernando Esquivel-Guadarrama
fernando.esquivel@uaem.mx

Specialty section:

This article was submitted to
Viral Immunology,
a section of the journal
Frontiers in Immunology

Received: 23 March 2019

Accepted: 04 July 2019

Published: 18 July 2019

Citation:

Padilla-Quirarte HO,
Lopez-Guerrero DV,
Gutierrez-Xicotencatl L and
Esquivel-Guadarrama F (2019)
Protective Antibodies Against
Influenza Proteins.
Front. Immunol. 10:1677.
doi: 10.3389/fimmu.2019.01677

The influenza A virus infection continues to be a threat to the human population. The seasonal variation of the virus and the likelihood of periodical pandemics caused by completely new virus strains make it difficult to produce vaccines that efficiently protect against this infection. Antibodies (Abs) are very important in preventing the infection and in blocking virus propagation once the infection has taken place. However, the precise protection mechanism provided by these Abs still needs to be established. Furthermore, most research has focused on Abs directed to the globular head domain of hemagglutinin (HA). However, other domains of HA (like the stem) and other proteins are also able to elicit protective Ab responses. In this article, we review the current knowledge about the role of both neutralizing and non-neutralizing anti-influenza proteins Abs that play a protective role during infection or vaccination.

Keywords: influenza A virus, neutralizing antibodies, non-neutralizing antibodies, influenza proteins, protective antibodies

INTRODUCTION

The influenza proteins are recognized as foreign by the immune system, and antibodies (Abs) against them are produced during vaccination or after a natural infection. The Ab response can be *neutralizing* or *non-neutralizing*. *Neutralization* refers to the reduction of viral infectivity exerted by an Ab when binding to a virus. *Neutralizing Abs* inhibit virion cell entry because their epitopes are located near the receptor-binding site (RBS) on the globular head of HA. They can also interfere with the conformational changes necessary to expose the fusion peptide on HA (anti-stalk Abs). Despite the fact that neutralizing Abs are protective, the term neutralization has been often misused as a synonym of protection. Actually, these terms point to very different processes: whereas neutralizing Abs are defined by *in vitro* assays (e.g., hemagglutination inhibition and microneutralization assays), the term protection is associated to the reduction of morbidity and mortality *in vivo*. In this context, a minor fraction of *non-neutralizing Abs* that are generated upon the recognition of other viral epitopes can also be protective by other mechanisms, such as those that do not involve interfering the virus-cellular receptor interaction like increasing phagocytosis, activating complement or promoting antibody-dependent cellular cytotoxicity (ADCC) (1).

Influenza Virus

The Influenza A Virus (IAV) is a negative-sense single-stranded RNA virus of the *Orthomyxoviridae* family. The virion contains eight gene segments, encoding for at least 11 viral proteins. These gene segments are associated to the nucleoprotein (NP) and the polymerases (PB1, PB2, and PA), which

form the ribonucleoprotein (vRNP) complex. The vRNP complex is surrounded by matrix protein 1 (M1), which forms the core of the virion. This structure is covered by a lipidic membrane acquired from the host cell. This membrane contains the glycoproteins HA and neuraminidase (NA), which jointly represent over ninety percent of the protein present in the membrane. Furthermore, matrix protein 2 (M2) forms a homotetrameric structure that crosses the viral lipidic membrane and functions as a pH-dependent ion channel (2). Each virion only contains approximately 20–60 M2-channels. Finally, few molecules of the nuclear export protein (NEP, formerly named NS2) are associated with M1 within the virion (3).

The IAV infects human epithelial cells in the respiratory tract by binding HA to the sialic acid residues present on their surface; this is followed by virus internalization through receptor-mediated endocytosis. Upon endosome acidification, HA undergoes conformational changes that allow it to expose the fusion peptide that promotes viral-endosomal membrane fusion. On the other hand, the IAV core is also acidified by the entry of protons through the M2-ion channel. Both processes allow the vRNPs to be released into the cytoplasm, from where they are transported to the nucleus via nuclear localization signals (NLS) present in all vRNPs. Once in the nucleus, positive sense RNA is transcribed into mRNAs and replicated to produce a full-length complementary replicative intermediate (cRNA) by the viral RNA-dependent RNA polymerase. Afterwards, the mRNAs exit the nucleus to be translated by ribosomes, and the cRNA will serve as template to produce viral RNA (vRNA). Newly synthesized viral proteins come back to nucleus to assemble vRNPs, which, assisted by the NEP protein, will be exported to the cytoplasm where they are now ready for the packaging process in the cell membrane. The budding process of the newly assembled virions is largely facilitated by the M1 protein that recruits the necessary viral and host cell components. Finally, the NA promotes the viral exit process by pruning the interactions between sialic acid and the newly formed virions (2, 4).

Other non-structural (NS) proteins are produced during the IAV infection cycle. They play major roles in modulating the immune system to facilitate the infection. NS1 inhibits type I interferons by binding directly to RIG-I (retinoic-acid-inducible gene-1) and/or impeding its ubiquitination by interacting with the E3 ligase TRIM25 (tripartite motif-containing protein 25) (5, 6). PB1-F2 protein has been shown to have proapoptotic activity in epithelial and immune cells, such as macrophages (7). Finally, the PA-X protein degrades the host transcripts in the nucleus (6).

There are two major mechanisms of IAV evolution: *antigenic drift* and *antigenic shift*. The antigenic drift occurs frequently because of the poor fidelity of RNA polymerase that generates point mutations in the HA and the NA, that allow the virus to escape from neutralizing Abs. Eventually, these mutations are introduced into the circulating viral strains. This mechanism makes it necessary the annual revision of seasonal influenza vaccines. On the contrary, the antigenic shift occurs rarely, and consists in the generation of a completely new antigenic strain by the reassortment of gene segments during co-infections with human, avian and swine viruses.

These evolutionary strategies are responsible for epidemics (antigenic drift) and pandemics (antigenic shift). The challenge posed by IAV is the generation of a “universal vaccine,” which could offer protection against any epidemic or pandemic strain (8).

Influenza Virus Vaccines

Currently, there are three types of licensed human influenza vaccines: trivalent/quadrivalent inactivated vaccines (TIV/QIV) live attenuated vaccines (LAIV) and the recombinant vaccine Flublok. TIV/QIV are administered intramuscularly. They are non-adjuvanted inactivated vaccines composed of three or four circulating influenza virus strains (H1N1, H3N2, B; or two B strains for QIV). The strains are grown individually in embryonated chicken eggs and manipulated to harbor all internal genes from the A/PR/8/34 (H1N1) virus and two HA and NA genes corresponding to the circulating strains each year. There are three types of inactivated vaccines: whole virus vaccines, split virus vaccines, and subunit vaccines. In whole-virus vaccines, the allantoic fluid is harvested after the culture, and the virus is chemically inactivated with formalin or β -propiolactone. Split-vaccines add an extra step with detergent to make it less reactogenic by removing RNA. In subunit-vaccines, the HA of each virus is further purified. On the other hand, LAIV consist of cold-adapted virus, and they are administered intranasally. They do not replicate well in the lower respiratory tract, but they do in the nasal cavities. Flublok is a trivalent recombinant hemmagglutinin influenza vaccine, licensed by the FDA (US Food and Drug Administration) in 2013, that contains HA antigens derived from the three influenza virus strains recommended by the World Health Organization (WHO) annually (9).

For seasonal vaccines, the main mechanism of protection is the induction of neutralizing Abs specific for the globular domain of HA. This parameter can be measured by hemagglutination inhibition or neutralization assays, where a serum titer ≥ 40 is correlated to protection. Unfortunately, the effectiveness of these vaccines depends on the accuracy of the virus strain selection process coordinated by the WHO. An inaccurate selection of strains may explain why the vaccines have shown low levels of protection in certain years (10).

B-Cell Response Against the Influenza Virus: Learnings From the Mouse Model

The first Abs that participate in clearing an influenza infection are the so-called *natural Abs*, which are polyreactive Abs, mainly IgM, secreted by CD5⁺ B-1 cells present in pleural and peritoneal cavities. These Abs are continuously produced in the absence of infection, and they have low affinity for the antigens (11). The role of natural Abs in the influenza infection was addressed by Baumgarth et al., who showed that the passive transfer of naïve serum from wild-type to IgM KO ($^{-/-}$) mice infected with influenza reduced the mortality in comparison to the controls (12). These Abs are present in airways in high levels, since they are transported to mucosal surfaces by poly-Ig-receptors located in the basolateral membrane of the alveolar epithelial cells (13). They could

neutralize the IAV directly, or lyse cells by fixing complement (14). However, the levels of natural Abs are usually low, and most pathogens can overcome this barrier and establish an infection.

For an influenza-specific B-cell response to occur, the antigen must travel to secondary lymph organs (SLO) like draining lymph nodes and/or mucosa-associated lymphoid tissues (MALT). There, specific B cells encounter the antigen for the first time; then, they are differentiated to antibody-secreting cells (ASC) (15). Once in the LN or the spleen, the antigen may be captured, by two main types of cells; subcapsular sinus macrophages (SSM) and medullary dendritic cells (MDC), which capture the antigen mostly opsonized by complement components and thus, facilitate its encounter with the B cells. Then, the virus is transported and handed to the follicular dendritic cells (FDC), which retain it for continuous antigen presentation during long periods of time. These cells serve as major promoters of center germinal formation (15, 16).

Once the influenza antigens reach the draining lymph nodes, two types of B cell responses take place: the extrafollicular (EF) and the germinal center (GC) responses. Within the first days of infection (48–72 hpi), Abs are secreted by extrafollicular plasmablasts (short-lived antibody secreting cells). These early specific Abs play an important role in dealing with primary infections, because they contribute to ameliorate the disease outcome. This is mainly a T-dependent response, although some minor T-independent responses have been documented (17).

On the other hand, some virus-specific B cells migrate toward the marginal zone of the B follicles, where they interact with CD4⁺ T cells triggering a germinal center reaction (GCR) that leads, late during the infection, to the generation of long-lived plasma cells that maintain high levels of high-affinity Abs, which is the most desirable consequence of vaccination or infection, along with long-lived memory B cells (18). Briefly, in the GCR, follicular helper T cells (Tfh), which express CD40L and cytokines like IL-4, IFN- γ , and TGF- β , induce immunoglobulin class switching of activated B cells. Moreover, Tfh and B cells physically interact via ICOS/ICOSL, PD-1/PD-L1, CD28/B7 and other co-stimulating signals, leading to IL-21 secretion. Jointly, these signals promote somatic hypermutation and affinity maturation, resulting in influenza-specific high-affinity-ASCs. At the same time, during the GCR, some ASCs differentiate into memory B cells, which can be defined as cells that have undergone antigen-driven proliferation and have then become non-proliferating cells. They can be induced by re-exposure to the antigen and afterwards proliferate and secrete Abs. (15).

During subsequent IAV infections, GC response from GC-derived memory B cells dominate the response, however, the role of the EF B cells cannot be discarded since it has been shown in an antigen-specific experimental mouse model that the GC-derived memory B cells pool can respond as EF in a secondary response (19). In humans, high throughput sequencing of the B cell repertoire after infection or vaccination could help to understand the dynamic of EF and GC responses.

ANTIBODIES AGAINST IAV EXTERNAL PROTEINS

HA-Specific Antibodies

HA from influenza viruses is a spike-shaped protein that extends from the surface of the virus. The HA precursor (HA0) trimerizes in the ER and in the virion surface is processed by tissue trypsin generating two polypeptides: HA1 and HA2, which interact through disulfide bonds. HA1 comprises the globular region of the molecule (head), which contains the RBS, and the upper part of the stem region. HA2 covers the major part of the stem region, and it contains the fusion peptide. Currently, 18 different serological IAV HA subtypes have been described, and they have been divided into two phylogenetic groups: group 1 (including H1, H2, H5) and group 2 (including H3 and H7). In humans, H1 and H3 are the most frequent HAs present in circulating strains, and they are the main components of inactivated seasonal vaccines. However, some HAs from avian viruses such as H5 and H7 (e.g., H5N1 and H7N9) have crossed the interspecies barrier infecting humans and causing occasional outbreaks (20, 21).

Antibodies Against the Globular Domain of HA

Classical neutralizing antibodies: original antigenic sin

Most of the classical neutralizing Abs against influenza are directed to the conformational epitopes on HA, particularly the globular domain, which has been well-characterized as the immunodominant region of this protein. Since the early eighties, using monoclonal Abs (mAbs) as a tool, five non-overlapping sites (Sb, Sa, Ca1, Ca2 and Cb, or A-E sites) were identified as the major regions recognized by neutralizing Abs (22–25). Sites Sa and Sb are located at the top of the globular domain of HA, while Ca1, Ca2, and Cb are located at the bottom of the head (22).

Using a mouse model, it was shown by Angeletti et al., that there is a hierarchy among the five antigenic sites of the HA molecule of PR8 virus (H1N1), that depends on the immune response progress, the genetic background and the way in which the antigen is formulated and delivered: Cb-specific B-cells are predominant in the immediate response after infection, but they are substituted by Sb-specific B-cells at day 21. This hierarchy was not influenced by CD4⁺ T cells, and it may change with different administration routes and different strains of mice (26). Later, Liu et al., analyzed the hierarchy of immunodominance for the HA of a post-2009 influenza pandemic strain, A/Michigan/45/2015 (H1N1) in several species including humans: while no specific immunodominance pattern was found with guinea pigs, Sb and Ca-specific Abs dominated the immune response in mice and the site Sa was dominant in ferrets. For humans it was reported a completely different pattern in which Sa and Sb-specific Abs dominated the antibody response (27). Similarly, for H3 virus, Broecker et al. found that the B site (analog to sites Sa and Sb in H1 HA) in the HA protein of the H3N2 strain that circulated in the 2017–2018 season was immunodominant pre and post-vaccination in humans that received seasonal vaccine. The same pattern of immunodominance was found with mice, but unlike reported by Angeletti et al., it was independent of genetic background and immunization route (28, 29).

Abs elicited against the HA globular domain during infection or vaccination usually are strain-specific, and they will hardly neutralize subsequent influenza virus strains (homosubtypic protection). This is explained by the selective pressure exerted by the immune system, which leads to the rise of new strains (with minor amino acid substitutions in the five neutralizing sites of HA head) that can avoid previous Abs (escape mutants). This evolutionary mechanism (antigenic drift) makes it necessary the annual reformulation of seasonal influenza vaccines.

Only specific Abs for the head of HA efficiently prevent infection, by blocking the HA-mediated attachment to the cell surface (26). Anti-HA Abs can also have an effect on the activity of other influenza-related proteins. Several authors have found both in humans and mice that anti-HA Abs can also interfere with the activity of neuraminidase (NA) by blocking virus binding to the surface bound NA-substrate or by sterically inhibiting NA access to the substrates (30–32).

An important feature of the neutralizing anti-IAV Ab response, predominantly involving the globular domain of HA, is the phenomenon called *original antigenic sin* (OAS). The term was coined in 1960 by Thomas Francis to describe the fact that in humans, influenza virus infections in childhood leaves an immunological imprint that results in high Abs titers against the childhood encountered virus after being boosted by new drifted virus (33, 34). These Abs are mainly directed against the conserved epitopes present in the different virus strains. A possible explanation for this phenomenon, is that there is a competition between memory B cells specific for the first strains and naïve cells specific for the new strain, which need to meet more requirements for activation, such as higher antigen doses (35). Another interesting hypothesis to explain the OAS, is that the T regulatory cells induced by the first antigen reduce the amount of the second antigen available to activate naïve B cells (36).

An example of OAS was observed in the most recent pandemic caused by an IAV H1N1 in 2009 (pH1N1/2009). As previously stated, the HA head does not induce a high level of cross-reactivity. However, the frequency of severe disease among elderly people infected with the pandemic strain was lower than it was among younger individuals, suggesting preexisting immunity. In this regard, IAV HA is more closely related to the 1918 pandemic virus A/South Carolina/1/1918 (H1N1) than HAs from seasonal strains, and those individuals who more likely experienced pre-1957 H1N1 strains had higher titers of neutralizing Abs to the 2009 H1N1 strain (37, 38). An interesting fact was that the main antigenic determinants of these Abs were located on the Sa site of the globular domain of HA, shared between the 1918 and 2009 strains (39).

Despite the fact that the term OAS was proposed almost 60 years ago, it is still valid, and elucidating the role of this phenomenon in infection and vaccination processes continues to be relevant. In a recent study Lindermann and Hensley found by using serum passive-transfer experiments in a mouse model, that Abs with an OAS phenotype were effective in neutralizing antigenically different influenza virus strains *in vivo*, indicating that OAS-Abs are an important mechanism of protection in secondary immune responses (40). However, according to two

other studies, this phenomenon seems to have no impact on the response to vaccination in humans (41, 42). Further studies are necessary to determine more precisely the role of OAS after infection or vaccination against IAV.

Anti-HA head broadly neutralizing antibodies

Despite the fact that most anti-HA head Abs are strain-specific, in 2009 the mAb S139/1 was isolated from a mouse immunized with an H3 virus. Surprisingly, this Ab neutralized multiple subtypes, including H1, H2 and H3 strains, and its epitope is located in the antigen site B near the RBS (43).

In the same way, the human mAb CH65 was isolated from an adult resident of the United States that had received the 2007 TIV. According to crystallographic studies with the A/H1N1/Solomon Islands/3/2006 strain, CH65 Ab mimics the physiologic interaction between sialic acid and HA, as this antibody binds directly to the sialic-acid pocket through its HCDR3. In this report, CH65 neutralized 30 out of 36 influenza H1N1 strains *in vitro* (44). Other receptor-binding site mAb (C05) was isolated by Ekiert et al. using phage antibody libraries from a human donor. The mAb C05 binds directly to RBS on HA using mainly its HCDR3 and with minor interaction through its HCDR1, and is capable to neutralize group 1 and group 2 influenza virus strains (45).

Furthermore, anti-head broadly neutralizing mAbs whose epitopes are farther from the RBS have been described. Ohshima et al. isolated mAbs F045-092 and F026-427 from human B lymphocytes. These mAbs showed activity against the H1N1, H3N2 and H5N1 viruses, and their epitopes were also found to be on the globular head of HA (46). D1-8 is a human mAb whose epitope is close to the D antigenic site, different from the RBS, and it is highly conserved among the H3N2 viruses. In mice, it has a better therapeutic effect than oseltamivir (47).

Antibodies Against the HA Stem

Anti-HA stem broadly neutralizing antibodies

In contrast to the globular domain of HA, the stem domain (or stalk domain) of HA is far less variable, and it has been shown to induce broadly neutralizing Abs (bnAbs). In 1993, Okuno et al. described for the first time a mAb (C179) specific for the HA stem region in mice. It had no hemagglutination inhibition activity (HAI), but it was capable of neutralizing H1 and H2 viruses (group 1) (48). Recently, a number of mAbs, which have displayed protective activity in mice and have a broad range of neutralization activity for group 1 (CR6261), group 2 (CR8020), and both groups of influenza viruses (FI6) (49–51), have been described in humans. Unfortunately, their epitopes are subdominant after infection or vaccination and, therefore, new strategies have been proposed to boost the generation of Abs against the stem domain.

Most human anti-stem Abs, particularly those against HAs from group 1 (e.g., CR6261 and F10), use the V_{H1–69} gene family. These broadly reactive Abs are characterized by a phenylalanine in position 54 at the HCDR2 region unique to the V_{H1–69} gene. This provides them with a unique ability to form hydrophobic interactions with the hydrophobic groove between HA1 and HA2, using only their heavy chains. Thus, they inhibit the

conformational changes necessary for the fusion of viral-cell membranes (52–54).

Regarding group 2 Abs, prototype human mAb CR8020 binds a different epitope from that of CR6261/F10. Although the epitope is also on the HA stem, it is closer to the virus membrane. This antibody uses both heavy and light chains to make contact with its epitope, and the fusion peptide accounts for 50% of the Van der Waals forces involved in the Fab-HA binding (50).

The human mAb FI6 recognizes both groups of HAs, since it is able to bind to their fusion peptide. This mAb was isolated from human plasmablasts. Its heavy and light chains correspond to the $V_{H3-30*18}$ and $V_{K4-1*01}$ gene families, respectively. Although this mAbs binding site overlaps with that of mAb CR6261/F10, FI6 makes contact only with the HCDR3 region, while CR6261/F10 encompasses all three HCDR regions (49). Recently, S9-1-10/5-1 was described as a human mAb that uses the gene V_{H4-59} family and displays specificity to both HA groups. Although it binds to the HA2 A-helix, apparently it does not inhibit the virus entry. Instead, it binds to HA on the surface of the infected cells, thus preventing the viral particle release (55).

Although the occurrence of anti-stem Abs is low after a seasonal infection or vaccination, several reports indicate that these Abs are boosted after sequential infections or immunizations with viruses containing different types of globular HA, but essentially the same stem HA (56). Recently, Nachbagauer et al. analyzed the cross-reactivity pattern of anti-HA Abs after an influenza infection in patients diagnosed with pH1N1/2009 or seasonal H3N2, and they found that a pH1N1 infection induces a broader response (against group 1 and group 2 HAs) than an H3N2 infection does. This can be explained because the 2009 pandemic strain had a novel HA head, compared with that of seasonal viruses, and thus, could boost the response against the HA stem region (57).

With respect to the 2009 pandemic vaccination, Cortina Ceballos et al. analyzed the B cell repertoire in individuals, with no previous exposure to pH1N1/2009, after they received the monovalent inactivated vaccine containing the pandemic strain (09 MIV). They reported heterosubtypic neutralizing seroconversion in 17% of the individuals. The phenomenon was associated to a clonal expansion of B cells that used the V_{H1-69} segment and to other cells involved in the generation of anti-stem Abs (58). In the same context, Li et al. analyzed B-cell responses from vaccine-induced plasmablasts in healthy adults after they had received 09 MIV. They observed high levels of cross-reactivity against the HA-stem domain. This cross-reactivity pattern occurred in the case of pandemic vaccination, and it was not seen with the seasonal TIV. Furthermore, they found that, just like seasonal vaccines (TIV), anti-stem Abs had arisen from preexisting memory B cells even before the emergence of the 2009 pandemic virus, which suggests that they were induced by previous strains (59).

Additionally, the repertoire of B cells from individuals vaccinated in consecutive years with the pandemic strain pH1N1/2009 was analyzed by Andrews et al. They showed that the individuals with low basal levels of Abs specific for this strain generated a broadly reactive response directed mainly against the HA stem. On the other hand, individuals with high levels of Abs

before vaccination correlated with a dominant response against the HA head domain after immunization. The authors suggest that the repertoire of anti-stem B cell memory is preexistent and that the immunodominance of the HA globular domain prevails with the subsequent encounters with the influenza virus (60). This observation echoes the dilemma of producing a universal vaccine that promotes the generation of anti-stem Abs or rather using the Abs in passive immunization strategies in infected individuals, since it is possible that consecutive challenges with seasonal strains of influenza will move the balance in favor of anti-head Abs.

It is well-known that anti-stem Abs are less permissive to virus escape, but Choi et al. identified three escape mutants in virus strain A/Perth/16/2009 (H3N2) after it was co-cultured *in vitro* with the human mAb 39.29, which neutralizes all IAV subtypes. The authors described that mutant Gly387Lys totally eradicates the antibody binding, while mutants Asp391Tyr and Asp391Gly increase the ability of HA to fuse membranes with just a slight interference in binding at low pH (61).

NA-Specific Antibodies

Neuraminidase is the second most abundant glycoprotein on the surface of the influenza virion. It is a homotetramer with a mushroom-like form, and it plays two major roles during the IAV infection: It promotes adhesion to the receptors on the epithelial cells because it degrades mucus, and it facilitates viral exit by breaking the interactions between sialic acid and the newborn virions. Neuraminidase inhibitors like oseltamivir act by inhibiting the last step and causing virus aggregation on the cell surface. Each NA monomer is composed of approximately 470 amino acids that form four domains: a short cytoplasmic N-terminal domain that is 100% homologous among influenza strains, a transmembrane hydrophobic domain, and a stem-shaped C-terminal domain of variable longitude, which ends in a globular domain where the enzymatic site is located (62).

Anti-NA Abs have historically been underestimated, due to the central role that HA has played in influenza research. However, for the last 50 years, important data have been gathered suggesting that anti-NA Abs can offer protection against the influenza infection. In 1968, Schulman et al. demonstrated that Abs against this protein are produced in mice after an IAV infection. The outcome of an infection in naïve mice improved when NA-immune serum was transferred to them (63). The same research group confirmed that anti-NA Abs were also present in humans after an influenza infection (64). Later, Murphy et al. investigated the role of anti-NA Abs in a clinical study carried out with volunteers, with low basal levels of anti-HA Abs and variable levels of anti-NA Abs. These subjects were infected with influenza virus A/NT/60/68 (H3N2), and the authors observed that the individuals who displayed minimal symptoms had higher levels of anti-NA Abs (65).

Recently, Chen et al. found in humans that seasonal vaccination induces a poor NA-specific B-cell response, whereas anti-NA B-cell responses after an IAV infection are similar (H1N1) or even higher (H3N2) when compared to HA-specific B-cell responses. The authors also found that anti-NA Abs were cross-reactive to NA proteins from most IAV strains and

that they showed prophylactic and therapeutic potential when evaluated *in vivo* (66).

NA-specific Abs induce infection-permissive immunity by limiting the viral load through interference with the exit of the virions. In other words, they do not prevent infection, but they contribute to ameliorate the clinical symptoms of disease. Among these Abs, those that are directed to the enzymatic site have the highest activity of neuraminidase inhibition (NAI), because they apparently limit the access of natural substrate to the catalytic site (67). Furthermore, anti-NA Abs are able to exert immune pressure within the globular domain of NA by promoting escape mutants (antigenic drift), which is an indirect proof that they play a role in immunity against IAV (68).

In the case of anti-NA Abs, there is also evidence of original antigenic sin. As stated previously, during the last IAV pandemic (pH1N1/2009), there was a low incidence of illness among elderly people. This was attributed to their previous exposure to similar IAV strains during childhood, which induced a recall response to the conserved domains of HA present in the strains. Similarly, Marcelin et al. found that NAI Abs were present in the sera from older people, and seroconversion was only registered in the age group ≥ 70 years after TIV vaccination. This provides evidence that NA-specific B cells from past strains were activated by the pH1N1/2009 virus, and they contributed to the protection process (69). In the same way, Rajendran et al., found that anti-NA Abs levels are directly proportional to age, and their reactivity are highest against influenza virus strains that more likely circulated during their childhood [A/South Carolina/1/1918 (H1N1), and A/Singapore/1/1957 (H2N2) in elderly; A/USSR/92/1977 (H1N1) and A/Philippines/2/1982 (H3N2) in adults] (31).

A unique opportunity to elucidate the independent contribution of the anti-NA Abs to the protection process was the 1968 Hong Kong IAV pandemic, during which a new virus (H3N2) emerged. It had a new HA, while the NA remained the same as in the circulating seasonal strain. Thus, evidence pointed out that anti-NA Abs played a key role in reducing the severity of the disease (70).

It is well-known that the gold standard for evaluation of vaccine efficacy is the HAI titer, where a value ≥ 40 is taken as protective by the FDA in the United States (71). Nonetheless and despite the lack of data regarding the contribution of anti-NA Abs in protection, Memoly et al. studied in humans the role of the NAI titer levels in predicting protection against influenza. They found that the same value of NAI titers (≥ 40) correlated better with the prediction of protection, even at higher levels than the HAI titer, which is only associated to a reduction of virus shedding. High levels of NAI titers also correlated with the reduction of the viral load and the duration and severity of the infection, among other symptoms (72). Similarly, Couch et al., confirmed by multivariate analysis that anti-NA Abs titers in serum and nasal secretions are independent predictors of immunity and protection to influenza in samples taken pre and post pandemic of 2009 (73). These results suggest that in addition to HAI, also NAI titers can serve as predictors of protection.

Anti-NA Abs are also produced in response to the administration of seasonal vaccines. Recently, Monto et al. showed that 37 and 6% of human recipients of TIV and LAIV, respectively, had Abs with NAI activity, whereas the values of HAI for these same groups were 77 and 21.2%, respectively. They also reported that after the 2007–2008 influenza season, NAI levels in subjects with confirmed infection rose to 41% for TIV, 63% for LAIV, and 76 % for unvaccinated subjects, whereas HAI levels were 18%, 77% and 97%, respectively (74).

Regarding cross-protection of anti-NA Abs, mice vaccinated with different recombinant NA resulted in reduction of mortality against influenza virus challenges with heterologous (not heterosubtypic) strains. This protection was dependent of specific-NA Abs, as shown by passive transference experiments (75). Additionally, Sandbulte et al. found that anti-N1 Abs can protect mice from a lethal challenge with the avian H5N1 subtype when previously immunized with a DNA vaccine encoding for N1 from human virus A/New Caledonia/20/99 (H1N1). Furthermore, they showed that human Abs detected in 81.6% (31/38) of the subjects were capable of inhibiting NA activity against the avian strain, suggesting that the incorporation of NA to TIV vaccines or the natural infection could offer protection against new pandemic strains such as H5N1(76). In this respect, Gillim-Rose and Subbarao debated Sandbulte's hypothesis pointing out that these data are still insufficient to predict a protective heterologous response to H5N1 in the human population. In consequence, forthcoming studies should focus on the magnitude and biological advantage of cross-reactive N1 Abs before considering the inclusion of this IAV protein in a vaccine (77).

Up to now, discussion has focused on the possible incorporation of NA in an anti-influenza vaccine. However, more information is required to determine the amount of antigen, the serologic data of NAI titers, and the type of vaccine to achieve the best protective immune response in humans. In this regard, present vaccines are designed for the production of anti-HA Abs, while the NA content has not yet been standardized (78). Attenuated vaccines present the same concern as a natural infection, since they contain a considerable higher proportion of HA than of NA (5:1) in the virion, which leads to an antigenic competition, where the HA-specific B-cell response overcomes the NA-specific B cell response (68, 79, 80). However, this antigenic superiority of HA over NA in terms of antibody production observed both in the natural infection and with vaccination is lost when proteins are administered separately and in the same proportion (81). Altogether, NA is a promissory candidate for the design of better vaccines against IAV. However, it seems that current data on NA-immunity is still insufficient. In this regard, for a more specific review, a recent publication addressed thoroughly the major knowledge gaps, pointing out the actions that should be taken on this matter (82).

Fc Receptors (FcR)-Mediated Effector Functions for HA- and NA-Antibodies

In addition to previously described mechanisms of protection for HA-Abs, indirect antiviral FcR-mediated effector functions

like ADCC, antibody-dependent cellular phagocytosis (ADCP) and complement mediated cell-cytotoxicity (CDCC) have been described both in humans and mice (83–92). Also, ADCC has been described for NA-Abs (87). Although, these mechanisms of protection will not be addressed further in this article, these effector antiviral function of HA- and NA-Abs may have an important role on protection against IAV infection.

Antibodies Against M2 Protein

Matrix protein 2 (M2) is the third most abundant protein on the IAV virion surface. It is a type III integral protein arranged as a homotetrameric channel linked by disulfide bonds, which function as proton selectors. They induce the acidification of the virions and consequently the dissociation of the vRNPs from matrix protein (M1) and their release into the cytoplasm during the entry phase of the IAV cycle. The M2 protein is 96 amino acids long, and it has three domains: a cytoplasmic C-terminal (54 aa), a transmembrane (19 aa), and a short and highly conserved N-terminal ectodomain (M2e, 23 aa). Antiviral drugs amantadine and rimantadine target M2, blocking the proton influx into the virion through an allosteric effect (93).

The density of M2 in the virion is low (approximately 60 molecules/virion) compared to the high concentration of HA or NA on the viral membrane. These major glycoproteins also exert an allosteric blockade of M2, which makes it difficult to be reached by B-cell receptors and thus, it generates minimal immunogenicity during a natural infection. However, the N-terminal ectodomain of M2 (M2e) has been targeted in the design of a “universal vaccine,” because it is highly conserved among influenza strains, and because the capacity of anti-M2e Abs to generate heterosubtypic protective responses has been observed in mice (94).

The immunogenicity of M2e was first reported in 1988 by Zebedee and Lamb. They described a mAb (14C2) that was produced in mice immunized with M2 protein plus adjuvant. This mAb recognized the ectodomain of the protein, and it was able to detect M2 on the virions, thus reducing viral growth. This was evidenced by the size reduction of lytic plaques when 14C2 was added to previously IAV-infected MDCK cells (95). Later, Treanor et al. proved that this antibody reduced lung viral titers when ascitic fluid was passively transferred to naïve mice that were afterwards challenged with IAV (96).

Abs against M2 are not neutralizing. Nonetheless, due to the high expression of M2 on the surface of infected cells, they can contribute to the protection process by promoting effector functions based on their Fc region. Lee *et al.* reported that anti-M2e Abs were not protective in Fc receptor common γ -chain deficient mice (FcR $\gamma^{-/-}$) in comparison to the high protection observed among wild-type mice in passive transfer experiments (97). In this context, El Bakkouri et al. reported in a mouse model that protection induced by these Abs depended on phagocytosis of infected cells by alveolar macrophages (AM) by engagement to the Fc receptors (Fc γ RIII for IgG1, and Fc γ RI and/or Fc γ RIV for IgG2a) present in these cells (98). Furthermore, NK cells can induce ADCC by binding to the Fc domain of anti-M2 Abs. Simhadri et al. showed that freshly isolated and cytokine-preactivated NK cells in presence of a

human anti-M2 antibody (1–10 mAb) can exert ADCC and secrete cytokines (99). The role of CDCC in M2e immunity is controversial: Jegerlehner et al. reported that anti-M2e Abs do not eliminate infected cells by CDCC (100), whereas Wang et al., reported that complement is necessary for an anti-M2e mAb to control lung viral titers in challenged mice (101).

Several reports in mice have shown that M2e can induce an efficient heterosubtypic protection. Different approaches have been used to determine this, such as coupling M2e to carrier proteins—like the hepatitis B virus core protein (HBc) (102)—or to flagellin (103); conjugated to nanoparticles of gold (104); inserted in VLPs (105); as DNA vaccines (106), and others. Recently, the efficacy of Abs against HA (induced by TIV), against NA (recombinant N1 and N2) and against M2 (M2e5XVLP) was compared in mice. It was found that immune sera against NA and M2e were superior in terms of improving heterosubtypic protection and survival than anti-HA Abs induced by the split seasonal vaccine. Interestingly, the co-administration of NA and M2e5XVLP immune sera gave rise to a synergistic heterologous protection effect (107).

In general, the levels of M2-specific Abs in sera of IAV infected patients are low and non-durable (108, 109). However, one study has suggested that anti-M2 Abs may increase with age after a pandemic strain appears. It is explained that a recall humoral response to this protein could be boosted, since the presence of anti-M2 Abs after infection with the pH1N1/2009 strain was detected in nearly 50% of the samples tested, even before anti-HA Abs specific to this strain could be identified (109).

Moreover, anti-M2e Abs have shown to be protective in humans. In a controlled challenged study, the administration of a specific anti-M2e IgG mAb (TCN-032), showed a reduction of 35% of symptoms compared to group that received placebo, when challenged with influenza virus A/Wisconsin/67/2005 (H3N2) (110). Also, several phase I and II clinical trials of M2e-based vaccines have shown to be safe and immunogenic in humans (103, 111, 112), and recently a phase I clinical trial started to evaluate a hepatitis B core-M2e-based vaccine in Russia (NCT03789539) (113).

ANTIBODIES AGAINST INTERNAL PROTEINS

The IAV infection induces Abs against internal and non-structural proteins, such as NP, M1, PB1-F2 and others (87, 114–116). Nevertheless, the protective role of these Abs is still unknown, although few studies in mice have shown that at least the anti-NP Abs can weakly help to clear influenza infection (117, 118).

The aa sequence of NP is conserved up to 90%, among various strains of influenza and heterosubtypic immunity (HSI) induced by this protein has been fully demonstrated in the mouse model, a feature that had been totally attributed to T cells (119–121). However, Rangel-Moreno et al. reported that T cells are insufficient to achieve HSI, and they proposed that non-neutralizing Abs contribute to decrease the severity of the illness by lowering viral titers, decreasing weight loss, and promoting

TABLE 1 | Mechanisms of action of protective antibodies against influenza virus proteins in mouse and humans.

Antibodies against	Mechanism	Confirmed with:	
		Mouse Abs	Human Abs
HA (head)	Neutralizing (strain specific)	✓ ^a	✓
	Broadly neutralizing	✓	✓
		S139/1 ^b (43) ^c	CH65, C05, F045-092, F026-427, D1-8 (44–47)
	Non-neutralizing		
	ADCC		
HA (stem)			
	ADCP		
	CDCC		(92)
	Inhibit NA activity	✓ (30, 32)	
	Block fusion	✓ C179 (48)	✓
NA			
	Broadly neutralizing		CR6261, CR8020, FI6, F10 (48–52)
	Non-neutralizing		
	ADCC		FI6 (84)
	ADCP	✓ (91)	✓ (91)
M2			
	CDCC	✓ (92)	✓ (92)
	Inhibit NA activity	✓ (32)	✓ (31)
	Not described		✓ (66)
	NI-activity, interfere with viral release	✓ (76)	✓ (66)
NP			
	ADCC		✓ (87)
	ADCP		✓ 1–10 (99)
	CDCC	✓ (98)	
	CDCC	✓ (101)	
NP			
	ADCC		✓ (87)
	ADCP		
	CDCC		
	Low activity (123)		

a. ✓ indicates that the mechanism of action has been confirmed.

b. mAb name.

c. Reference in parenthesis.




FIGURE 1 | Summary of the protection mechanisms of neutralizing and non-neutralizing Abs specific for different proteins of the influenza virus. **(A)** Abs that neutralize the infection **(B)** Abs that control the infection by indirect mechanisms as ADCC, CDCC or ADCP **(C)** Abs that prevent the virus budding. The symbol ? indicates the mechanism of protection is controversial.

the recovery of mice by helping CD8 T cells to expand after the heterosubtypic challenge (122). Furthermore, Carragher et al. analyzed the role of anti-NP Abs on HSI by vaccinating mice in the absence of T cells with recombinant nucleoprotein (rNP). They found that HSI was still present. However, it was lost when the Abs were absent, and it was recovered by transfer of rNP-immune serum (118).

Previous studies have shown that NP can be expressed on the surface of influenza virus-infected cells (123–125), however evidence for Fc-mediated effector functions of anti-NP Abs is controversial. Regarding ADCC, despite Varderven *et al* reported that healthy individuals had anti-NP and anti-M1 Abs capable of activating NK cells through FCγRIII, these Abs had no killing activity on target cells *in vitro* (116). Contrarily, Jegaskanda et al. found in human sera higher titers of NP-specific ADCC-Abs reactive to avian influenza strain H7N9, as compared with HA- or NA-specific ADCC-Abs reactive to the same strain. In addition, these Abs correlated with ADCC-Abs reactive to NP in the seasonal influenza viruses (H1N1 and H3N2), suggesting that they could be induced by seasonal infections or by vaccination (87). Also, Bodewes et al., reported no complement-dependent cell cytotoxicity using a human mAb specific for NP *in vitro* (124), while Yewdell et al. found low CDCC activity with five different mouse NP-mAbs in complement-mediated ⁵¹Cr microcytotoxicity assays (123).

LaMere et al. described in mice that anti-NP IgG Abs also contribute to the protection against IAV in a mechanism dependent on CD8⁺ T cells and Fc receptors (117). This can be explained because anti-NP Abs can associate with viral proteins (probably from dying infected cells) forming immune complexes (IC), which are captured by dendritic cells via FcγR, and promoting a sustained antigen presentation to CD8 T cells. All of this contributes to memory development (126). In accordance with this, when aged mice with a depressed cytotoxic T lymphocyte (CTL) response received artificial IC consisting of a NP-specific mAb and the influenza virus, the CTL response was restored, along with an enhanced dendritic cell function and an increment of IFN-γ by CD4⁺ and CD8⁺ T cells (127).

Finally, other internal and non-structural proteins like PA-X and PB1-F2 have shown to induce Abs, even though their role in protection has not been determined. In 2012, protein PA-X was identified as a product of the ribosomal frameshifting of IAV segment 3, and, at least in animal models, it modulates viral growth and suppresses antiviral responses. In 2016, the first evidence of PA-X expression in humans was the high titers

of specific Abs to this protein found in sera from patients infected during the 2003 H7N7 outbreak occurred in The Netherlands (115). Moreover, the presence of Abs against the PB1-F2 protein were confirmed by immunoprecipitation and immunofluorescence assays in human convalescent sera and experimental infected mice (114).

A summary of protective Abs against influenza virus and their mechanisms of protection is shown in **Table 1** and **Figure 1**, respectively.

CONCLUSION

Both neutralizing and non-neutralizing Abs can offer heterosubtypic protection against IAV. However, the Abs that recognize highly conserved epitopes are subdominant during the course of a natural infection or after vaccination. Therefore, efforts to build a universal vaccine with these antigenic determinants are being made, along with strategies for increasing their immunity. Nevertheless, despite the significant advances on the knowledge of heterosubtypic humoral immunity and the biology of B cells in animal models, further studies in humans are needed to define the viability of using them as a component of an anti-IAV universal vaccine or as a therapeutic measure.

AUTHOR CONTRIBUTIONS

HP-Q conceived this review and wrote the manuscript. FE-G directed the project and participated editing all the sections. DL-G created the figure and critically read the manuscript. LG-X critically read and edited the manuscript. All authors approved the final version of the manuscript. This work was done as a complementary academic activity of the Ph.D. program of HP-Q.

FUNDING

This work was supported by grants from SEP-CONACYT (2015-01-257420) and SEP-PRODEP (Redes temáticas de colaboración de CA, 2015). HP-Q is a Ph.D. student of the Biochemical Sciences Program, Instituto de Biotecnología, UNAM, and was supported by a CONACYT Scholarship (375463).

ACKNOWLEDGMENTS

We thank Jesus Martínez Barnetche for his critical point of view of this review.

REFERENCES

- Hangartner L, Zinkernagel RM, Hangartner H. Antiviral antibody responses: the two extremes of a wide spectrum. *Nat Rev Immunol.* (2006) 6:231–43. doi: 10.1038/nri1783
- Medina RA, García-Sastre A. Influenza A viruses: new research developments. *Nat Rev Microbiol.* (2011) 9:590–603. doi: 10.1038/nrmicro2613
- Yasuda J, Nakada S, Kato A, Toyoda T, Ishihama A. Molecular assembly of influenza virus: association of the NS2 protein with virion matrix. *Virology.* (1993) 196:249–55. doi: 10.1006/viro.1993.1473
- Samji T. Influenza A: understanding the viral life cycle. *Yale J Biol Med.* (2009) 82:153–9.
- Jureka AS, Kleinpeter AB, Cornilescu G, Cornilescu CC, Petit CM. Structural basis for a novel interaction between the NS1 protein derived

- from the 1918 influenza virus and RIG-I. *Structure*. (2015) 23:2001–10. doi: 10.1016/j.str.2015.08.007
6. Klemm C, Boergeling Y, Ludwig S, Ehrhardt C. Immunomodulatory nonstructural proteins of influenza A viruses. *Trends Microbiol.* (2018) 26:624–636. doi: 10.1016/j.tim.2017.12.006
 7. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, et al. A novel influenza A virus mitochondrial protein that induces cell death. *Nat Med.* (2001) 7:1306–12. doi: 10.1038/nm1201-1306
 8. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. *Nat Immunol.* (2006) 7:449–55. doi: 10.1038/ni1343
 9. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. *Influenza Other Respir Viruses.* (2008) 2:211–9. doi: 10.1111/j.1750-2659.2008.00053.
 10. Wong SS, Webby RJ. Traditional and new influenza vaccines. *Clin Microbiol Rev.* (2013) 26:476–92. doi: 10.1128/CMR.00097-12
 11. Choi YS, Baumgarth N. Dual role for B-1a cells in immunity to influenza virus infection. *J Exp Med.* (2008) 205:3053–64. doi: 10.1084/jem.20080979
 12. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. *J Exp Med.* (2000) 192:271–80. doi: 10.1084/jem.192.2.271
 13. Baumgarth N. How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth. *Immunol Rev.* (2013) 255:82–94. doi: 10.1111/imr.12094
 14. Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. *J Virol.* (2007) 81:3487–94. doi: 10.1128/JVI.02128-06
 15. Chiu C, Ellebedy AH, Wrammert J, Ahmed R. B cell responses to influenza infection and vaccination. *Curr Top Microbiol Immunol.* (2015) 386:381–98. doi: 10.1007/82_2014_425
 16. Heesters BA, van der Poel CE, Das A, Carroll MC. Antigen Presentation to B Cells. *Trends Immunol.* (2016) 37:844–854. doi: 10.1016/j.it.2016.10.003
 17. Lee BO, Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Makris M, Sprague F, et al. CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection. *J Immunol.* (2005) 175:5827–38. doi: 10.4049/jimmunol.175.9.5827
 18. Kurosaki T, Kometani K, Ise W. Memory B cells. *Nat Rev Immunol.* (2015) 15:149–59. doi: 10.1038/nri3802
 19. Sze DM, Toellner KM, García de Vinuesa C, Taylor DR, MacLennan IC. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. *J Exp Med.* (2000) 192:813–21. doi: 10.1084/jem.192.6.813
 20. Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. *Science.* (2012) 335:1463. doi: 10.1126/science.1218888
 21. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med.* (2013) 368:1888–97. doi: 10.1056/NEJMoa1304459
 22. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). *Cell.* (1982) 31(2 Pt 1):417–27. doi: 10.1016/0092-8674(82)90135-0
 23. Lubeck MD, Gerhard W. Topological mapping antigenic sites on the influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies. *Virology.* (1981) 113:64–72. doi: 10.1016/0042-6822(81)90136-7
 24. Yewdell JW, Gerhard W. Antigenic characterization of viruses by monoclonal antibodies. *Annu Rev Microbiol.* (1981) 35:185–206. doi: 10.1146/annurev.mi.35.100181.001153
 25. Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. *Nature.* (1981) 290:713–7. doi: 10.1038/290713a0
 26. Angeletti D, Gibbs JS, Angel M, Kosik I, Hickman HD, Frank GM, et al. Defining B cell immunodominance to viruses. *Nat Immunol.* (2017) 18:456–463. doi: 10.1038/ni.3680
 27. Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. *J Clin Invest.* (2018) 128:4992–4996. doi: 10.1172/JCI122895
 28. Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P. Immunodominance of antigenic site B in the hemagglutinin of the current H3N2 influenza virus in humans and mice. *J Virol.* (2018) 92:e01100–18. doi: 10.1128/JVI.01100-18
 29. Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, et al. Antibody responses toward the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets, and humans. *J Virol.* (2019). 93:e01673–18. doi: 10.1128/JVI.01673-18
 30. Kosik I, Yewdell JW. Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms. *Virology.* (2017) 500:178–183. doi: 10.1016/j.virol.2016.10.024
 31. Rajendran M, Nachbagauer R, Ermler ME, Bunduc P, Amanat F, Izikson R, et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin. *MBio.* (2017) 8:16. doi: 10.1128/mBio.02281-16
 32. Wohlbold TJ, Chromikova V, Tan GS, Meade P, Amanat F, Comella P, et al. Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice. *J Virol.* (2016) 90:851–61. doi: 10.1128/JVI.02275-15
 33. Francis T. On the Doctrine of Original Antigenic Sin. *Proc Am Philos Soc.* (1960) 104:572–578.
 34. Fazekas de St. G, Webster RG. Disquisitions of Original Antigenic Sin. I. Evidence in man. *J Exp Med.* (1966) 124:331–45. doi: 10.1084/jem.124.3.331
 35. Cobey S, Hensley SE. Immune history and influenza virus susceptibility. *Curr Opin Virol.* (2017) 22:105–111. doi: 10.1016/j.coviro.2016.12.004
 36. Ndifon W. A simple mechanistic explanation for original antigenic sin and its alleviation by adjuvants. *J R Soc Interface.* (2015) 12:112. doi: 10.1098/rsif.2015.0627
 37. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. *Science.* (2010) 328:357–60. doi: 10.1126/science.1186430
 38. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N Engl J Med.* (2009) 361:1945–52. doi: 10.1056/NEJMoa0906453
 39. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. *J Virol.* (2010) 84:3127–30. doi: 10.1128/JVI.02184-09
 40. Linderman SL, Hensley SE. Antibodies with 'original antigenic sin' properties are valuable components of secondary immune responses to influenza viruses. *PLoS Pathog.* (2016) 12:e1005806. doi: 10.1371/journal.ppat.1005806
 41. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature.* (2008) 453:667–71. doi: 10.1038/nature06890
 42. O'Donnell CD, et al. Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus. *Clin Vaccine Immunol.* (2014) 21:737–46. doi: 10.1128/CVI.00790-13
 43. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. *PLoS Pathog.* (2009) 5:e1000350. doi: 10.1371/journal.ppat.1000350
 44. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. *Proc Natl Acad Sci USA.* (2011) 108:14216–21. doi: 10.1073/pnas.1111497108
 45. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. *Nature.* (2012) 489:526–32. doi: 10.1038/nature11414
 46. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. Naturally occurring antibodies in humans can neutralize a variety of

- influenza virus strains, including H3, H1, H2, and H5. *J Virol.* (2011) 85:11048–57. doi: 10.1128/JVI.05397-11
47. Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, et al. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. *J Virol.* (2014) 88:6743–50. doi: 10.1128/JVI.03562-13
 48. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J Virol.* (1993) 67:2552–8.
 49. Corti D, Voss J, Gambin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science.* (2011) 333:850–6. doi: 10.1126/science.1205669
 50. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. *Science.* (2011) 333:843–50. doi: 10.1126/science.1204839
 51. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. *Science.* (2009) 324:246–51. doi: 10.1126/science.1171491
 52. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. *Curr Opin Virol.* (2012) 2:134–41. doi: 10.1016/j.coviro.2012.02.005
 53. Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. *PLoS Pathog.* (2014) 10:e1004103. doi: 10.1371/journal.ppat.1004103
 54. Avnir Y, Watson CT, Glanville J, Peterson EC, Tallarico AS, Bennett AS, et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. *Sci Rep.* (2016) 6:20842. doi: 10.1038/srep20842
 55. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, et al. A broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release. *EBioMedicine.* (2017) 17:182–91. doi: 10.1016/j.ebiom.2017.03.007
 56. Palese P, Wang TT. Why do influenza virus subtypes die out? A hypothesis. *MBio.* (2011) 2:5. doi: 10.1128/mBio.00150-11
 57. Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. *Nat Immunol.* (2017) 8:464–473. doi: 10.1038/ni.3684
 58. Cortina-Ceballos B, Godoy-Lozano EE, Téllez-Sosa J, Ovilla-Muñoz M, Sámano-Sánchez H, Aguilar-Salgado A, et al. Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain. *Genome Med.* (2015) 7:124. doi: 10.1186/s13073-015-0239-y
 59. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. *Proc Natl Acad Sci USA.* (2012) 109:9047–52. doi: 10.1073/pnas.1118979109
 60. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly affects broadly protective B cell responses to influenza. *Sci Transl Med.* (2015) 7:316ra192. doi: 10.1126/scitranslmed.aad0522
 61. Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, et al. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. *PLoS Pathog.* (2016) 12:e1005702. doi: 10.1371/journal.ppat.1005702
 62. Air GM. Influenza neuraminidase. *Influenza Other Respir Viruses.* (2012) 6:245–56. doi: 10.1111/j.1750-2659.2011.00304.x
 63. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. *J Virol.* (1968) 2:778–86.
 64. Kilbourne ED, Christenson WN, Sande M. Antibody response in man to influenza virus neuraminidase following influenza. *J Virol.* (1968) 2:761–2.
 65. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. *N Engl J Med.* (1972) 286:1329–32. doi: 10.1056/NEJM197206222862502
 66. Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. *Cell.* (2018) 173:417–29 e10. doi: 10.1016/j.cell.2018.03.030
 67. Marcelin G, Sandbulte MR, Webby RJ. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. *Rev Med Virol.* (2012) 22:267–79. doi: 10.1002/rmv.1713
 68. Eichelberger MC, Wan H. Influenza neuraminidase as a vaccine antigen. *Curr Top Microbiol Immunol.* 2015. 386: p. 275–99. doi: 10.1007/82_2014_398
 69. Marcelin G, Bland HM, Negovetich NJ, Sandbulte MR, Ellebedy AH, Webb AD, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. *J Infect Dis.* (2010) 202:1634–8. doi: 10.1086/657084
 70. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. *Lancet.* (1973) 1:623–5. doi: 10.1016/S0140-6736(73)92196-X
 71. Cox RJ. Correlates of protection to influenza virus, where do we go from here? *Hum Vaccin Immunother.* (2013) 9:405–8. doi: 10.4161/hv.22908
 72. Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. *MBio.* (2016) 7:e00417–16. doi: 10.1128/mBio.00417-16
 73. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. *J Infect Dis.* (2013) 207:974–81. doi: 10.1093/infdis/jis935
 74. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. *J Infect Dis.* (2015) 212:1191–9. doi: 10.1093/infdis/jiv195
 75. Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. *MBio.* (2015) 6:e02556. doi: 10.1128/mBio.02556-14
 76. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. *PLoS Med.* (2007) 4:e59. doi: 10.1371/journal.pmed.0040059
 77. Gillim-Ross L, Subbarao K. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? *PLoS Med.* (2007) 4:e91. doi: 10.1371/journal.pmed.0040091
 78. Gérentes L, Kessler N, Aymard M. Difficulties in standardizing the neuraminidase content of influenza vaccines. *Dev Biol Stand.* (1999) 98:189–96; discussion 197.
 79. Getie-Kebtie M, Sultana I, Eichelberger M, Alterman M. Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines. *Influenza Other Respir Viruses.* (2013) 7:521–30. doi: 10.1111/irv.12001
 80. Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirion antigenic competition. *J Virol.* (1993) 67:5721–3.
 81. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. *J Virol.* (1989) 63:1239–46.
 82. Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, et al. NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines? *MBio.* (2018) 9:2. doi: 10.1128/mBio.02332-17
 83. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for *in vivo* protection. *J Clin Invest.* (2016) 126:605–10. doi: 10.1172/JCI84428
 84. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus *in vivo*. *Nat Med.* (2014) 20:143–51. doi: 10.1038/nm.3443

85. Jegaskanda S, Laurie KL, Amarasekera TH, Winnall WR, Kramski M, De Rose R, et al. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. *J Infect Dis.* (2013) 208:1051–61. doi: 10.1093/infdis/jit294
86. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. *J Immunol.* (2013) 190:1837–48. doi: 10.4049/jimmunol.1201574
87. Jegaskanda S, Co MDT, Cruz J, Subbarao K, Ennis FA, Terajima M. Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza A viruses that are directed toward the nucleoprotein. *J Infect Dis.* (2017) 215:818–23. doi: 10.1093/infdis/jiw629
88. Terajima M, Co MD, Cruz J, Ennis FA. High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. *J Infect Dis.* (2015) 212:1052–60. doi: 10.1093/infdis/jiv181
89. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. *J Immunol.* (2014) 193:469–75. doi: 10.4049/jimmunol.1400432
90. Ana-Sosa-Batiz F, Vandervan H, Jegaskanda S, Johnston A, Rockman S, Laurie K, et al. Influenza-specific antibody-dependent phagocytosis. *PLoS ONE.* (2016) 11:e0154461. doi: 10.1371/journal.pone.0154461
91. Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner. *MBio.* (2016) 7:5. doi: 10.1128/mBio.01624-16
92. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, et al. Complement-dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. *J Virol.* (2011) 85:13463–7. doi: 10.1128/JVI.05193-11
93. Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, et al. Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. *J Virol.* (2015) 89:3700–11. doi: 10.1128/JVI.02576-14
94. Deng L, Cho KJ, Fiers W, Saelens X. M2e-based universal influenza A vaccines. *Vaccines.* (2015) 3:105–36. doi: 10.3390/vaccines3010105
95. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. *J Virol.* (1988) 62:2762–72.
96. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. *J Virol.* (1990) 64:1375–7.
97. Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, et al. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. *Immunology.* (2014) 143:300–9. doi: 10.1111/imm.12310
98. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. *J Immunol.* (2011) 186:1022–31. doi: 10.4049/jimmunol.0902147
99. Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, et al. A human anti-M2 antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine secretion by resting and cytokine-preactivated Natural Killer (NK) cells. *PLoS ONE.* (2015) 10:e0124677. doi: 10.1371/journal.pone.0124677
100. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. *J Immunol.* (2004) 172:5598–605. doi: 10.4049/jimmunol.172.9.5598
101. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. *Antiviral Res.* (2008) 80:168–77. doi: 10.1016/j.antiviral.2008.06.002
102. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. *Nat Med.* (1999) 5:1157–63. doi: 10.1038/13484
103. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. *Vaccine.* (2011) 29:5145–52. doi: 10.1016/j.vaccine.2011.05.041
104. Tao W, Hurst BL, Shakyia AK, Uddin MJ, Ingrole RS, Hernandez-Sanabria M, et al. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. *Antiviral Res.* (2017) 141:62–72. doi: 10.1016/j.antiviral.2017.01.021
105. Gao X, Wang W, Li Y, Zhang S, Duan Y, Xing L, et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. *Antiviral Res.* (2013) 98:4–11. doi: 10.1016/j.antiviral.2013.01.010
106. Tompkins SM, Zhao ZS, Lo CY, Mispelon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. *Emerg Infect Dis.* (2007) 13:426–35. doi: 10.3201/eid1303.061125
107. Kim YJ, Ko EJ, Kim MC, Lee YN, Kim KH, Jung YJ, et al. Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection. *Biochem Biophys Res Commun.* (2017) 493:393–8. doi: 10.1016/j.bbrc.2017.09.011
108. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. *Viral J.* (2006) 3:102. doi: 10.1186/1743-422X-3-102
109. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K, et al. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. *J Infect Dis.* (2014) 209:986–94.
110. Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. *J Infect Dis.* (2015) 211:1038–44. doi: 10.1093/infdis/jiu539
111. *Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults.* Available online at: <https://ClinicalTrials.gov/show/NCT00921947> (accessed November 13, 2017).
112. *Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults.* Available online at: <https://ClinicalTrials.gov/show/NCT00819013> (accessed November 13, 2017).
113. Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e. *Vaccine.* (2015) 33:3398–406. doi: 10.1016/j.vaccine.2015.04.073
114. Krejnosová I, Gocníkova H, Bystrická M, Blaskovicová H, Poláková K, Yewdell J, et al. Antibodies to PB1-F2 protein are induced in response to influenza A virus infection. *Arch Virol.* (2009) 154:1599–604. doi: 10.1007/s00705-009-0479-5
115. Khurana S, Chung KY, Coyle EM, Meijer A, Golding H. Antigenic fingerprinting of antibody response in humans following exposure to highly pathogenic H7N7 avian influenza virus: evidence for Anti-PA-X antibodies. *J Virol.* (2016) 90:9383–93. doi: 10.1128/JVI.01408-16
116. Vandervan HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What lies beneath: antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. *EBioMedicine.* (2016) 8:277–90. doi: 10.1016/j.ebiom.2016.04.029
117. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. *J Immunol.* (2011) 186:4331–9. doi: 10.4049/jimmunol.1003057
118. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. *J Immunol.* (2008) 181:4168–76. doi: 10.4049/jimmunol.181.6.4168
119. Shu LL, Bean WJ, Webster RG. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. *J Virol.* (1993) 67:2723–9.
120. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. *Immunity.* (2006) 24:5–9. doi: 10.1016/j.immuni.2005.12.005

121. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. *Proc Natl Acad Sci USA*. (1985) 82:1785–9. doi: 10.1073/pnas.82.6.1785
122. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, Moquin A, et al. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. *J Immunol*. (2008) 180:454–63. doi: 10.4049/jimmunol.180.1.454
123. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. *J Immunol*. (1981) 126:1814–9.
124. Bodewes R, Geelhoed-Mieras MM, Wrammert J, Ahmed R, Wilson PC, Fouchier RA, et al. *In vitro* assessment of the immunological significance of a human monoclonal antibody directed to the influenza A virus nucleoprotein. *Clin Vaccine Immunol*. (2013) 20:1333–7. doi: 10.1128/CI.00339-13
125. Virelizier JL, Allison AC, Oxford JS, Schild GC. Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. *Nature*. (1977) 266:52–4. doi: 10.1038/266052a0
126. León B, Ballesteros-Tato A, Randall TD, Lund FE. Prolonged antigen presentation by immune complex-binding dendritic cells programs the proliferative capacity of memory CD8 T cells. *J Exp Med*. (2014) 211:1637–55. doi: 10.1084/jem.20131692
127. Zheng B, Zhang Y, He H, Marinova E, Switzer K, Wansley D, et al. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. *J Immunol*. (2007) 179:6153–9. doi: 10.4049/jimmunol.179.9.6153

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Padilla-Quirarte, Lopez-Guerrero, Gutierrez-Xicotencatl and Esquivel-Guadarrama. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.